FGFR3 and neoplasm: The phase II lung-MAP substudy (SWOG S1400D, NCT02965378) and a phase Ib clinical study (NCT00979134) with AZD4547 FGFRi revealed single Sq-NSCLC patients with FGFR3 S249C who achieved PR (for 1.5 months with ~ 32% tumor shrinkage) (11) or SD (2.6-month progression-free survival [PFS] and 12% tumor shrinkage) (23).